| [1] |
Mizrahi JD, Surana R, Valle JW, et al. Pancreatic cancer[J]. Lancet, 2020, 395(10242): 2008-2020. DOI: 10.1016/S0140-6736(20)30974-0.
pmid: 32593337
|
| [2] |
Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3): 229-263. DOI: 10.3322/caac.21834.
|
| [3] |
Miller KD, Ortiz AP, Pinheiro PS, et al. Cancer statistics for the US Hispanic/Latino population, 2021[J]. CA Cancer J Clin, 2021, 71(6): 466-487. DOI: 10.3322/caac.21695.
|
| [4] |
Lucas AL, Shakya R, Lipsyc MD, et al. High prevalence of BRCA1 and BRCA2 germline mutations with loss of heterozygosity in a series of resected pancreatic adenocarcinoma and other neoplastic lesions[J]. Clin Cancer Res, 2013, 19(13): 3396-3403. DOI: 10.1158/1078-0432.CCR-12-3020.
pmid: 23658460
|
| [5] |
Momozawa Y, Sasai R, Usui Y, et al. Expansion of cancer risk profile for BRCA1 and BRCA2 pathogenic variants[J]. JAMA Oncol, 2022, 8(6): 871-878. DOI: 10.1001/jamaoncol.2022.0476.
pmid: 35420638
|
| [6] |
Holter S, Borgida A, Dodd A, et al. Germline BRCA mutations in a large clinic-based cohort of patients with pancreatic adenocarcinoma[J]. J Clin Oncol, 2015, 33(28): 3124-3129. DOI: 10.1200/JCO.2014.59.7401.
pmid: 25940717
|
| [7] |
Daly MB, Pal T, Berry MP, et al. Genetic/familial high-risk assessment: breast, ovarian, and pancreatic, version 2.2021, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2021, 19(1): 77-102. DOI: 10.6004/jnccn.2021.0001.
|
| [8] |
Hustedt N, Durocher D. The control of DNA repair by the cell cycle[J]. Nat Cell Biol, 2016, 19(1): 1-9. DOI: 10.1038/ncb3452.
pmid: 28008184
|
| [9] |
Parsels LA, Engelke CG, Parsels J, et al. Combinatorial efficacy of olaparib with radiation and ATR inhibitor requires PARP1 protein in homologous recombination-proficient pancreatic cancer[J]. Mol Cancer Ther, 2021, 20(2): 263-273. DOI: 10.1158/1535-7163.MCT-20-0365.
pmid: 33268569
|
| [10] |
Mateo J, Lord CJ, Serra V, et al. A decade of clinical development of PARP inhibitors in perspective[J]. Ann Oncol, 2019, 30(9): 1437-1447. DOI: 10.1093/annonc/mdz192.
pmid: 31987398
|
| [11] |
Golan T, Hammel P, Reni M, et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer[J]. N Engl J Med, 2019, 381(4): 317-327. DOI:10.1056/NEJMoa1903387.
|
| [12] |
孙琦, 李文倩, 解友邦, 等. 化疗后骨髓抑制机制的研究进展[J]. 国际肿瘤学杂志, 2023, 50(1): 33-36. DOI: 10.3760/cma.j.cn371439-20221005-00006.
|
| [13] |
Patel HP, Barrett A, Mauer E, et al. Homologous recombination repair pathway alterations and their relationship to homologous recombination deficiency in advanced pancreatic cancer patients.[J]. J Clin Oncol, 2022, 40(4S):609-609. DOI: 10.1200/JCO.2022.40.4_SUPPL.609.
|
| [14] |
Mirza MR, Monk BJ, Herrstedt J, et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer[J]. N Engl J Med, 2016, 375(22): 2154-2164. DOI: 10.1056/NEJMoa1611310.
|
| [15] |
Lan Y, Xia Z, Shao Q, et al. Synonymous mutations promote tumorigenesis by disrupting m6A-dependent mRNA metabolism[J]. Cell, 2025, 188(7): 1828-1841.e15. DOI: 10.1016/j.cell.2025.01.026.
|
| [16] |
张通, 李晓勇, 陈艳军, 等. 不可逆电穿孔消融术联合程序性死亡蛋白-1抑制剂及化疗在局部进展期胰腺癌的临床疗效[J]. 实用医学杂志, 2023, 39(9): 1153-1158. DOI: 10.3969/j.issn.1006-5725.2023.09.016.
|
| [17] |
刘绪林, 刘桂举. 吉西他滨联合替吉奥术后辅助治疗对胰腺癌患者免疫功能及血清细胞迁移诱导透明质酸结合蛋白、Klotho的影响[J]. 癌症进展, 2023, 21(10): 1086-1089. DOI: 10.11877/j.issn.1672-1535.2023.21.10.12.
|
| [18] |
Luchini C, Brosens LAA, Wood LD, et al. Comprehensive characterisation of pancreatic ductal adenocarcinoma with microsatellite instability: histology, molecular pathology and clinical implications[J]. Gut, 2021, 70(1): 148-156. DOI: 10.1136/gutjnl-2020-320726.
pmid: 32350089
|
| [19] |
Reiss KA, Mick R, Teitelbaum U, et al. Niraparib plus nivolumab or niraparib plus ipilimumab in patients with platinum-sensitive advanced pancreatic cancer: a randomised, phase 1b/2 trial[J]. Lancet Oncol, 2022, 23(8):1009-1020.DOI:10.1016/S1470-2045(22)00369-2.
pmid: 35810751
|
| [20] |
Tobalina L, Armenia J, Irving E, et al. A meta-analysis of reversion mutations in BRCA genes identifies signatures of DNA end-joining repair mechanisms driving therapy resistance[J]. Ann Oncol, 2021, 32(1): 103-112. DOI: 10.1016/j.annonc.2020.10.470.
pmid: 33091561
|
| [21] |
Thakar T, Moldovan GL. The emerging determinants of replication fork stability[J]. Nucleic Acids Res, 2021, 49(13): 7224-7238. DOI: 10.1093/nar/gkab344.
pmid: 33978751
|
| [22] |
Chang HHY, Pannunzio NR, Adachi N, et al. Non-homologous DNA end joining and alternative pathways to double-strand break repair[J]. Nat Rev Mol Cell Biol, 2017, 18(8): 495-506. DOI: 10.1038/nrm.2017.48.
|
| [23] |
Biegała Ł, Gajek A, Marczak A, et al. PARP inhibitor resistance in ovarian cancer: underlying mechanisms and therapeutic approaches targeting the ATR/CHK1 pathway[J]. Biochim Biophys Acta Rev Cancer, 2021, 1876( 2): 188633. DOI: 10.1016/j.bbcan.2021.188633.
|
| [24] |
Paul S, Sinha S, Kundu CN. Targeting cancer stem cells in the tumor microenvironment: an emerging role of PARP inhibitors[J]. Pharmacol Res, 2022, 184: 106425. DOI: 10.1016/j.phrs.2022.106425.
|
| [25] |
Mirza MR, Åvall Lundqvist E, Birrer MJ, et al. Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial[J]. Lancet Oncol, 2019, 20(10): 1409-1419. DOI: 10.1016/S1470-2045(19)30515-7.
pmid: 31474354
|
| [26] |
Higuchi T, Flies DB, Marjon NA, et al. CTLA-4 blockade synergizes therapeutically with PARP inhibition in BRCA1-deficient ovarian cancer[J]. Cancer Immunol Res, 2015, 3(11): 1257-1268. DOI: 10.1158/2326-6066.CIR-15-0044.
pmid: 26138335
|
| [27] |
Konstantinopoulos PA, Barry WT, Birrer M, et al. Olaparib and α- specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial[J]. Lancet Oncol, 2019, 20(4): 570-580. DOI: 10.1016/S1470-2045(18)30905-7.
pmid: 30880072
|
| [28] |
Vena F, Jia RC, Esfandiari A, et al. MEK inhibition leads to BRCA2 downregulation and sensitization to DNA damaging agents in pancreas and ovarian cancer models[J]. Oncotarget, 2018, 9(14): 11592-11603. DOI: 10.18632/oncotarget.24294.
pmid: 29545922
|
| [29] |
Fang Y, McGrail DJ, Sun C, et al. Sequential therapy with PARP and WEE1 inhibitors minimizes toxicity while maintaining efficacy[J]. Cancer Cell, 2019, 35(6): 851-867.e7. DOI: 10.1016/j.ccell.2019.05.001.
pmid: 31185210
|
| [30] |
Pulliam N, Fang F, Ozes AR, et al. An effective epigenetic-PARP inhibitor combination therapy for breast and ovarian cancers independent of BRCA mutations[J]. Clin Cancer Res, 2018, 24(13): 3163-3175. DOI: 10.1158/1078-0432.CCR-18-0204.
pmid: 29615458
|
